1-5 of 5
Ingemar Lagerlöf, MD
Close
Sort by
Journal Articles

Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial

Karin Fjorden, Sara Ekberg, Nevzeta Kuric, Karin Ekstroem Smedby, Ingemar Lagerlöf, MD, Thomas S. Larsen, MD, Judit M. Jørgensen, MD PhD, Peter de Nully Brown, MD PhD, Mats Jerkeman, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33.
https://doi.org/10.1182/blood-2020-133359
Published: 2020
Journal Articles

Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients

Fredrik Ellin, MD MSc, Knut B. Smeland, Tove Wästerlid, MD PhD, Jacob H. Christensen, MD, Judit Jørgensen, MD PhD, Pär L. Josefsson, Harald Holte, MD PhD, Yngvild Nuvin Blaker, MD PhD, Jacob H. Grauslund, Jon Bjoern, Daniel Molin, Ingemar Lagerlöf, MD, Karin Ekstrom Ekstroem Smedby, Katherine Colvin, Gita Thanarajasingam, MD, Matthew J Maurer, MS, Thomas M. Habermann, MD, Kevin Song, MD, Katie Yuan Zhu, BSc, Alina S Gerrie, MD MPH, Chan Y. Cheah, Tarec Christoffer C. El-Galaly, MD, Lasse H. Jakobsen, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4113.
https://doi.org/10.1182/blood-2019-127995
Published: 2019
Journal Articles

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Matthew Beasley, MD, Michael Bayne, MD, Tim M. Illidge, MDPhD, Noelle O'Rourke, MD, Ingemar Lagerlöf, MD, Roman Hajek, MD PhD, Wojciech Jurczak, MD PhD, Ella Willenbacher, MD, Unn Merete Fagerli, MD PhD, Aleš Obr, MD, Johan Blakkisrud, MSc, Ayca Muftuler Løndalen, MD, Lisa Rojkjaer, MD, Åse Østengen, Nils Bolstad, MD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Renate Galleberg, MD, Stine Nygaard Rudå, Harald Holte, Jr., MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2879.
https://doi.org/10.1182/blood-2018-99-110555
Published: 2018
Journal Articles

Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients

Lasse H. Jakobsen, Fredrik Ellin, Knut B. Smeland, Tove Wästerlid, Jacob H. Christensen, Judit Jørgensen, MD PhD, Pär L. Josefsson, Harald Holte, Jr., MD PhD, Yngvild N. Blaker, Jacob H. Grauslund, Jon Bjørn, Daniel Molin, Ingemar Lagerlöf, MD, Karin Ekstroem Smedby, MDPhD, Katherine Colvin, Gita Thanarajasingam, MD, Alina S. Gerrie, MD MPH, Chan Y. Cheah, Tarec C. El-Galaly
Journal: Blood
Blood (2018) 132 (Supplement 1): 452.
https://doi.org/10.1182/blood-2018-99-111748
Published: 2018
Journal Articles

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Arne Kolstad, MD PhD, Ulf Madsbu, MD, Matthew Beasley, MD, Michael Bayne, MD, Tim M. Illidge, MDPhD, Noelle O'Rourke, MD, Ingemar Lagerlöf, MD, Roman Hájek, MD, Wojciech Jurczak, PhDMD, Ella Willenbacher, MD, Johan Blakkisrud, MSc, Ayca Muftuler Løndalen, MD, Lisa Rojkjaer, MD, Laurie Baylor Curtis, MSc, Marianne Bloma, MSc, Simon Turner, PhD, Nils Bolstad, MD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Unn Merete Fagerli, MD, Renate Galleberg, MD, Stine Nygaard Rudå, Harald Holte
Journal: Blood
Blood (2017) 130 (Supplement 1): 2769.
https://doi.org/10.1182/blood.V130.Suppl_1.2769.2769
Published: 2017